Talos™ Thoracic Stent Graft System Gains CFDA Green-Path

On September 27, Talos™ Thoracic Stent Graft System (“Talos™”), self-developed by MicroPort Endovascular (Shanghai) Co., Ltd. (“MicroPort Endovascular”), was approved to enter the special Green-Path by China Food and Drug Administration (“CFDA”), which is rapid-track of review and approval procedure for innovative medical devices. The Green-Path will significantly expedite the approval time and meanwhile it demonstrated the recognition of Chinese government authorities in Talos™.

The traditional treatment of aortic dissection is to replace aorta in lesion segment by open surgery, which has high mortality rate and high incidence rate of complications due to large trauma. Thoracic endovascular aneurysm repair (“TEVAR”) features small incision, short operative time, and fast postoperative recovery, resulting in easier operation and lower mortality rate. Thus, TEVAR has gradually taken place of the traditional open surgery to become the preferred choice of treating Type B aortic dissection. But subject to the current technology, differences in pathophysiology of the disease and individual anatomical, the treatment using stent graft also has its own limitations: The lesion segment of aortic dissection is usually very long involving descending aorta and even abdominal aorta, however the existing thoracic stent grafts are often not long enough to completely cover the lesions, failing to open the distal true lumen and keep the blood of whole aorta vascular flowing smoothly after primary tear occlusion. But, if using long stent graft in the TEVAR, it will affect the blood supply of thoracic spinal cord and lumbar spinal cord, increasing the risk of spinal cord ischemia after the surgery. MicroPort® Endovascular’s Talos™ extents the covered length of the SG (Maximum 260mm) to open the distal true lumen and ensure the patency of the aorta, and at the same time innovatively adopts micropores design at the distal end of the SG to ensure the distal branch vessels (e.g., intercostal arteries) patency so as to reduce the incidence of spinal cord ischemia.
MicroPort® CardioFlow Attends 2017 PCR London Valves

On September 24, MicroPort Shanghai CardioFlow Medtech Co., Ltd. ("MicroPort® CardioFlow") attended the PCR London Valves to display its in-house developed VitaFlow™ Transcatheter Aortic Valve and Delivery System ("VitaFlow™"). PCR London Valves is the world’s largest educational meeting focused on the care of patients with valvular heart disease and specifically addressing percutaneous valve interventions. More than 3,000 experts and scholars from over 60 countries attended the congress.

The representative of MicroPort® CardioFlow delivered a speech of “the Engineering Challenges in Bicuspid Aortic Valves” in the session of “TAVI Unfinished Business.” The report contained two parts – the first part analyzed the engineering challenges of TAVI products in treating bicuspid aortic valve patients from five angles including incomplete valve expansion, paravalvular leakage, annulus rupture, instable valve deployment and long-term durability of the valve. The second part combined engineering science with the clinical needs of bicuspid aortic valve patients to demonstrate the excellent efficacy of VitaFlow™ in the treatment of bicuspid aortic valve, due to its innovative valve design that can effectively reduce the perivalvular leakage.

VitaFlow™ has completed one-year clinical follow-up in China and it is expected that the excellent result of clinical trials in China will lay a solid foundation for the clinical studies of VitaFlow™ II in China and Europe in 2018. In August 2016, VitaFlow™ was granted the Green-Path by the China Food and Drug Administration ("CFDA"), a special fast-track procedure for innovative medical devices to gain CFDA approval, and is expected to gain CFDA approval in 2018.
**First Case of Firehawk® in Tibet Completed**

On September 6, the first PCI case of Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") in Tibet Autonomous Region was successfully completed in Chinese Armed Police Force of Tibet Autonomous Region Hospital. Firehawk® is a stent in-house developed by Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®").

Tibetans are more likely to develop atherosclerosis of coronary artery due to their living conditions and diet habits. They live in the Tibet Plateau with 4,000 to 5,000 meters in altitude, and under such cold, low oxygen and low pressure living condition, the red blood cell would increase, leading to blood viscosity, slow blood flow and even microcirculation disturbance. Besides, they largely rely on food high in salt, fat and calorie, but lacking of vitamin and microelement, which would also increase the risk of atherosclerosis of coronary artery.

The coronary accessory of MicroPort® was first used in Chinese Armed Police Force of Tibet Autonomous Region Hospital for coronary angiogram in April 2017, and the first PCI case of Firehawk® marks the its coverage of all the provinces in the Chinese mainland. As the leading coronary stent provider in China, MicroPort® is committed to offering high-quality and more affordable solutions for patients with coronary heart disease and will continue to organize free clinic, donation activities, training courses, and surgery demonstrations to improve the medical treatment in minority areas to save more patients or improve their life quality.
The First Case of Firehawk® in Kazakhstan Completed

The first case of Firehawk® in Kazakhstan was successfully completed in National Scientific Medical Center in Astana, Kazakhstan. Firehawk® is a drug-eluting stent in-house developed by MicroPort®.

Dr. Linda Lin, First Vice President of MicroPort® International Business, said: "The outcome of the first Firehawk® case in Kazakhstan won high recognition from local physicians and patients, which paves the way for MicroPort® to further promote its products in Kazakhstan and even the whole Middle Asia. We will continue to introduce more high-quality medical devices to Kazakhstan and other countries involved in the "Belt and Road" initiative, to offer better service to patients."
First Post-market Implantation of Castor® Successfully Completed

The first post-market implantation of Castor® Branched Aortic Stent-Graft System ("Castor®"), in-house developed by MicroPort® Endovascular, was recently successfully completed by Director Xiaoqiang Li of the Second Affiliated Hospital of Soochow University. The product gained the regulatory approval from China Food and Drug Administration in June 2017 to officially enter the China market.

Director Xiaoqiang Li said: "Castor® extends the proximal landing zone to healthy area near the LSA, reducing the risk of retrograde dissection. The unibody design of Castor® can achieve double anchoring of LSA and thoracic aorta, preventing the stent graft from sliding into the false lumen, and reducing the risk of long-term migration." The launch of Castor® marks a significant step forward in using endovascular repair to treat aortic arch, making breakthroughs in a key area clinicians have spent many years to research and explore.
MSC CompassAnalyzer™ PSA Completes Patient Enrollment

MicroPort Sorin CRM (Shanghai) Co., Ltd. ("MSC"), a joint venture of MicroPort*, recently completed the patient enrollment for the clinical trial of its in-house developed CompassAnalyzer™ Pacing System Analyzer ("CompassAnalyzer™ PSA"). The clinical trial is the first pre-market multi-center clinical trial launched by MSC since the implementation of China’s Quality Control Regulations of Clinical Trials for Medical Devices from June 1, 2016. Zhongshan Hospital of Shanghai Fudan University (principal investigator), Ruijin Hospital of Shanghai Jiao Tong University, and East Hospital of Shanghai Tongji University participated in the clinical trial and over 100 patients have been enrolled.

The pacing system analyzer ("PSA") is external equipment needed in pacemaker implantation for physicians to evaluate electrical parameters of pacemaker leads. In recent years, with the phase out of the imported products that used to monopolize the market, there has been no portable and easy-to-use PSA in the market for a long period. So, physicians are looking forward to the launch of the domestically made CompassAnalyzer™ PSA in the China market to meet such an urgent need. Once launched in China, CompassAnalyzer™ PSA will facilitate physicians, especially those in regional hospitals, to perform pacemaker procedures.
MicroPort®
Hosts Satellite Meeting in CAS 2017

From September 1 to September 3, MicroPort® Orthopedics attended the 2017 Annual Congress of Chinese Arthroplasty Society ("CAS2017") in Tianjin and hosted a satellite meeting about knee prosthesis.

During the knee session, MicroPort® Orthopedics held a satellite meeting themed on "patient satisfaction – how knee prosthesis impacts the postoperative effect," which attracted wide attention from experts in attendance. Professor Yixin Zhou of Peking University Orthopedic Department and Beijing Jishuitan Hospital was invited as the lecturer to present on how the medial pivot knee achieves flexion stability and wear-limiting design.

EVOLUTION® was built on around 20 years of excellent clinical history of the first-generation ADVANCE® Medial-Pivot Knee System ("ADVANCE®"), with more prosthesis systems to choose from, which offers ideal solutions to patients with orthopedic diseases. EVOLUTION® was officially launched in the China market in 2015 and has been carried out clinical applications in several domestic hospitals. President of MicroPort® Orthopedics China Zixin Weng said: "It has become the main focus of the joint prosthesis field on how to improve function and drive patient satisfaction. With its excellent clinical performance, EVOLUTION® has won high recognition from experts in the joint surgery field. We will further promote the use of EVOLUTION® in China to promote the development of China’s joint surgery industry and benefit more patients."
**MicroPort® Orthopedics**  
**Hosts 2017 Asia Pacific Didactic Meeting**

On August 26, MicroPort® Orthopedics hosted Asia Pacific Didactic Meeting in Macao. More than 60 orthopedic experts from the Chinese mainland, Hong Kong, Macao, Australia, the Philippines, Malaysia, Japan, South Korea and other regions were gathered together to exchange ideas on the design rationale and surgical techniques of Medical Pivot Total Knee Replacement System as well as the clinical advantages and surgical techniques of SuperPath™ Micro-posterior Total Hip Arthroplasty ("SuperPath™").
MicroPort® Orthopedics Holds Medial Pivot Knee Roadshow

From August 24 to August 26, MicroPort® Orthopedics invited Professor Geoffrey Dervin, the Orthopedic Director of Affiliated Hospital University of Ottawa, for the Medial Pivot Knee System Roadshow activities held in four provinces of China - Hangzhou, Shanghai, Zhengzhou and Beijing. The roadshow activities, consisting of live surgery demonstrations and well-prepared lectures, aimed at helping orthopedic surgeons to get a deeper understanding in the cutting-edge technologies and development trend of total knee replacement. A great many of the domestic and overseas orthopedic experts were attracted to participate in the event.

The key to a successful total knee replacement is patient satisfaction which results from prosthesis stability and function recovery such as going up and down stairs and walking on flat ground. This roadshow of medial pivot total knee replacement system allowed more domestic and overseas surgeons to understand the importance of medial pivot knee in total knee replacement as well as the excellent performance of MicroPort® Orthopedics’ EVOLUTION® Medial Pivot Total Knee System. Up to date, over 550,000 MicroPort® Orthopedics’ Medial Pivot Knees have been implanted globally. According to a study evaluating long-term clinical and radiographic outcomes of the medial pivot knee system published in The Knee, the results demonstrate excellent clinical outcomes for both satisfaction (95%) and survivorship (98.8%) at 17 years with patients noting a great sense of stability and comfort during regular activities. Zixin Weng, President of MicroPort® Orthopedics China, said: "We will continue to host academic activities to provide a platform for domestic and overseas knee replacement experts to exchange ideas, so as to help promote the development of China's joint surgery industry and provide patients with better orthopedic solutions."
Canadian Orthopedic Expert Professor Paul Beaule Visits MicroPort® Orthopedics for Academic Exchange

From September 14 to September 17, Professor Paul Beaule, Orthopedic Director of University of Ottawa Hospital, attended the 2017 Shanghai International Hip Symposium, and participated in a two-day academic exchange at the invitation of MicroPort® Orthopedics to discuss the hot topics and shared his clinical experience related to hip arthroplasty products and techniques of MicroPort® Orthopedics with over 60 orthopedic experts from several top hospitals and academic institutions in Shanghai.

Professor Chuan He of Shanghai Ruijin Hospital, who is also Head of the Youth Committee of Shanghai Joint Surgery Society said: "Minimally invasive joint replacement technique is becoming increasingly popular in China as it reduces pain and facilitates a faster return to function for patients. I hope that MicroPort® Orthopedics will organize more such kind of academic events to provide a platform for clinicians and enterprises to strengthen mutual communication and cooperation to help develop more innovative products and technologies to benefit more patient." The salon focused on the clinical follow-up data of MicroPort® Orthopedics’ hip prosthesis, surgical skills of SuperPath™ technique in hemi hip arthroplasty, and case studies of old fracture. Professor Beaule demonstrated the advantages of MicroPort® Orthopedics’ hip products with large amount of follow-up data, which further enhanced the experts’ understanding and recognition in its products.
MicroPort® Orthopedics
Hosts SuperPath™ Hip Arthroplasty and Fast Recovery Seminar

On September 17, MicroPort® Orthopedics hosted SuperPath™ Minimally Invasive Hip Arthroplasty and Fast Recovery Seminar in the First Affiliated Hospital of Soochow University. The symposium focused on the advantages and surgical tips of SuperPath™. Around 100 experts from Jiangsu, Beijing, Guangxi, Jiangxi, Shandong and Henan provinces attended the event. Meanwhile over 200 people watched online by allinmd.cn.

As the world’s first total hip arthroplasty minimally invasive technique that facilitates a faster return to function for patients, SuperPath™ technique not only offers patients with small incision, but also provides added advantages like preservation of the external rotators, decreased operative time, decreased intra-operative blood loss, increased post-operative stability, as well as decreased post-operative recovery time and pain. SuperPath™ technique has been used in 25 provinces and cities of China, and an increasingly more surgeons have mastered the technique, allowing more patients to get a faster return to function with reduced complications.
MicroPort® EP Attends 2017 Guangdong Medical Association Cardiology Academic Annual Meeting to Display Columbus™

On September 8, Shanghai MicroPort EP MedTech Co., Ltd. ("MicroPort® EP") attended the 2017 Guangdong Medical Association Cardiology Academic Annual Meeting with more than 800 professionals and clinicians in attendance to exchange ideas on the latest academic advancement and future development trend of the cardiology field. During the meeting, MicroPort® EP displayed its in-house developed Columbus™ 3D EP Navigation System ("Columbus™") and invited many experts to share their clinical experience with the system, which attracted wide attention from the attendees.

As an edge tool in the EP radiofrequency ablation, the 3D navigation system has been recognized by an increasingly more physicians and has brought benefit to a lot of arrhythmia patients. Columbus™ is China’s first domestically developed 3D EP navigation system that features real time electromagnetic device tracking with cardiac motion compensation, which fills gaps in the field of domestically made EP devices and effectively lowers the medical cost for patients. As the only domestic company that provides a complete solution of cardiac EP treatment, MicroPort® EP will continue to strive for innovation and perfection to provide better arrhythmia solutions for patients and physicians.
MicroPort® Hosts
Ninth Aortic Intervention International Forum

From August 21 to August 25, MicroPort® hosted the 9th Aorta Intervention International Forum in three cities of China including Shanghai, Beijing and Changsha. During the forum, surgeons and distributors from Argentina and Dominican Republic were invited to visit Fuwai Hospital of Chinese Academy of Medical Sciences and the Second Xiangya Hospital of Central South University for academic exchange.

The Latin American surgeons said this academic exchange was rewarding and fruitful and they would apply the medical concept and surgical techniques learnt in this activity to clinical applications to serve more local patients. Dr. Lin said: "MicroPort® has been hosting the aortic intervention international forums for several consecutive years and the academic exchange between Chinese and foreign surgeons has always played an important role in these events, by which MicroPort® aims to build a platform for academic exchange and medical education. With the promotion of the 'Belt and Road' initiative, we hope that more experts from countries involving in the 'Belt and Road' initiative and Latin American countries along the 'Maritime Silk Road' can come to China for academic exchange, and jointly push the development of aorta interventional therapy."
MicroPort® Hosts
Supply Chain Innovation Summit

From September 18 to September 20, MicroPort® hosted the 2017 MicroPort® Supply Chain Innovation Summit in its headquarters. With the theme "Focus and Innovation," the conference aims to promote the strategic cooperation between MicroPort® and the suppliers while enhancing mutual communications on technical innovation. More than 200 people from about 100 suppliers attended the meeting to seek for marketing opportunities and win-win strategies.

The main aim of the congress is to enhance the mutual understanding and cooperation between the suppliers and MicroPort®. The three-day congress enhanced the suppliers' understanding in MicroPort® and promoted mutual communications, laying a solid foundation for closer cooperation. In the wake of "mass entrepreneurship and innovation," MicroPort® will draw a new blueprint with the suppliers for bilateral collaborations.
For more information, please contact:

Martin Sun
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

Leanne Li
Board Secretary & VP of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com